Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.100
Neutral
RSI(14)
51.409
Neutral
STOCH(KDJ)(9,3,3)
49.448
Sell
ATR(14)
0.198
High Vlolatility
CCI(14)
42.674
Neutral
Williams %R
26.791
Buy
TRIX(12,20)
0.373
Sell
StochRSI(14)
0.000
Sell
Aethlon Medical Inc
AEMD2.145USD
-0.125-5.51%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
27.81KMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Aethlon Medical Inc
Currency: USD Updated: 2026-03-27Key Insights
Aethlon Medical Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 11.50.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aethlon Medical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Aethlon Medical Inc Highlights
StrengthsRisks
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Fairly Valued
The company’s latest PE is -0.04, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.62.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
11.500
Target Price
+406.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Aethlon Medical Inc is 6.83, ranking 109 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.67
Operational Efficiency
2.77
Growth Potential
6.78
Shareholder Returns
6.92
Aethlon Medical Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Aethlon Medical Inc is 7.19, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.04, which is -89.19% below the recent high of -0.00 and -193.02% above the recent low of -0.13.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 103/208
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Aethlon Medical Inc is 6.00, ranking 175 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 12.38, with a high of 15.00 and a low of 9.75.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
11.500
Target Price
+434.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
92
Total
4
Median
7
Average
Company name
Ratings
Analysts
Aethlon Medical Inc
AEMD
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
36
Edwards Lifesciences Corp
EW
34
Veeva Systems Inc
VEEV
33
Thermo Fisher Scientific Inc
TMO
29
1
2
3
...
19
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Aethlon Medical Inc is 8.98, ranking 8 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.61 and the support level at 1.53, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.240
Sell
MA10
2.214
Sell
MA20
1.991
Buy
MA50
2.216
Sell
MA100
2.870
Sell
MA200
6.928
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Aethlon Medical Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 5.57%, representing a quarter-over-quarter decrease of 90.04%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aethlon Medical Inc is 1.50, ranking 187 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.53. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.47
VaR
+9.33%
240-Day Maximum Drawdown
+94.56%
240-Day Volatility
+469.17%
Return
Best Daily Return
60 days
+12.72%
120 days
+14.87%
5 years
+97.30%
Worst Daily Return
60 days
-9.89%
120 days
-23.49%
5 years
-53.10%
Sharpe Ratio
60 days
-0.33
120 days
-2.18
5 years
-0.67
Risk Assessment
Maximum Drawdown
240 days
+94.56%
3 years
+94.56%
5 years
+99.56%
Return-to-Drawdown Ratio
240 days
+5.55
3 years
-0.12
5 years
-0.19
Skewness
240 days
+3.40
3 years
+2.89
5 years
+2.78
Volatility
Realised Volatility
240 days
+469.17%
5 years
+245.14%
Standardised True Range
240 days
+45.42%
5 years
+41.35%
Downside Risk-Adjusted Return
120 days
-318.73%
240 days
-318.73%
Maximum Daily Upside Volatility
60 days
+80.71%
Maximum Daily Downside Volatility
60 days
+60.86%
Liquidity
Average Turnover Rate
60 days
+20.66%
120 days
+10.88%
5 years
--
Turnover Deviation
20 days
+61.60%
60 days
-39.11%
120 days
-67.95%
Peer Comparison
Healthcare Equipment & Supplies
Aethlon Medical Inc
AEMD
6.23 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
